Professor Limmroth discusses brain atrophy in multiple sclerosis

Jan 27, 2014 EST

Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis' Gilenya® (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis (MS) - brain volume loss, lesion activity (measure by magnetic resonance imaging - MRI), relapse rates and disability progression. Improvements were seen in patients who switched from standard interferon (interferon beta-1a) treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study. 

Trending NOW

Real Time Analytics